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Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents
Introduction
The order Anura (frogs and toads) currently contains 6660 well characterized species [1] and their skin secretions represent a vast reservoir of compounds with therapeutic potential for drug development. More than 1000 frog skin peptides have been described that possess antimicrobial activity with varying degrees of cytotoxicity against eukaryotic cells and it is postulated that they defend the host against invasion by pathogenic microorganisms in the environment [2, 3] . It is now appreciated that these peptides are multi-functional and they may also display immunomodulatory, antioxidant, and chemoattractive properties [3, 4] . In particular, several such peptides that were first identified on the basis of their antimicrobial activities have subsequently been found to display insulinotropic effects both in vitro using BRIN-BD11 clonal β cells and in vivo in both lean and insulin-resistant obese mice (reviewed in [4, 5] ). Consequently, these hostdefense peptides show potential for development into drugs for the treatment of patients with Type 2 diabetes mellitus (T2DM).
Peptide glycine-leucine-amide (PGLa) was first identified in skin secretions of the South African frog Xenopus laevis [6] and subsequently othologs have been isolated from a wide range of species belonging to the genus Xenopus (reviewed in [7] ). PGLa is best known for its broadspectrum antibacterial and antifungal activities and for its ability to act synergistically with magainin peptides [8, 9] . Skin secretions of the octoploid frog Xenopus amieti contain two paralogous peptides related to PGLa: PGLa-AM1 (GMASKAGSVLGKVAKVALKAAL.NH 2 ) and PGLa-AM2 (GMASTAGSVLGKLAKAVAIGAL.NH 2 ) [10] . The more cationic PGLa-AM1 shows greater growth-inhibitory potency against Escherichia coli and Staphylococcus aureus [10] and the peptide is also active against several oral pathogens at concentrations that do not affect the viability of oral fibroblasts [11] . The possibility that PGLa-AM1 may show 5 potential for development into a drug for the treatment of T2DM is suggested by the observation that PGLa-AM1 stimulates the release of the potent incretin peptide glucagon-like peptide-1 from the GLUTag murine enteroendocrine cell line at concentrations that are not toxic to the cells [12] . The aim of the present study was to investigate the insulinotropic actions of PGLa-AM1 in vitro using BRIN-BD11rat clonal β-cells [13] , 1.1B4 human-derived pancreatic β-cells [14] , and dispersed isolated mouse islets and in vivo using both lean mice and mice fed a high fat diet to produce obesity and insulin resistance.
One of the major disadvantages of naturally occurring peptides as therapeutic agents is their relatively low potency and bioavailability but these limitations may be circumvented to varying degrees by the design of appropriate analogues [15] . Although lacking secondary structure in aqueous solution, PGLa adopts an amphipathic α-helical conformation in a membrane-mimetic solvent (50% trifluoroethanol-water) or in the presence of negatively charged phosphatidylcholine /phosphatidylglycerol (3:1) vesicles [16] . Secondary structure prediction using the AGADIR algorithm [17] indicates that PGLa-AM1 has the propensity to adopt a stable α-helix from Val 9 to Leu
22
. Previous studies with analogues of other α-helical, frog skin host-defense peptides have shown that increasing cationicity by substitution of appropriate neutral or acidic amino acid residues by L-Lysine may produce more potent and effective insulin-releasing peptides [5, [18] [19] [20] . Consequently, effects of increasing cationicity, by the substitutions by L-lysine of Ala 14 and Ala 20 within the α-helical domain and Lys 3 outside the domain, on the insulin-releasing and glucose-lowering activities of the peptide were investigated.
In addition, the mechanism of action and effects of the peptides on proliferation and apoptosis in BRIN-BD11 cells were determined. 
Materials and Methods
Peptide synthesis and purification
PGLa-AM1 and its [A3K], [A14K] and [A20K] analogues were supplied in crude form
by GL Biochem Ltd (Shanghai, China) and were purified to near homogeneity (>98% purity) by reversed-phase HPLC by reversed-phase HPLC on a (2.2-cm x 25-cm) Vydac 218TP1022 (C-18) column (Grace, Deerfield, IL, USA) under the conditions previously described [11, 12] . The identities of all peptides were confirmed by MALDI-TOF mass spectrometry using a Voyager DE PRO instrument (Applied Biosystems, Foster City, USA).
In vitro insulin release studies using BRIN-BD11 and 1.1B4 cells
The procedure for studying the effects of peptides on the release of insulin from BRIN-BD11 rat clonal β-cells (passages 15-20) and 1.1B4 human-derived pancreatic β-cells (passages 25-28) has been described in detail previously [13, 14] . Incubations with purified synthetic peptides (10 -12 -3 x 10 -6 µM; n = 8) were carried out for 20 min at 37 ˚C using Krebs-Ringer bicarbonate (KRB) buffer supplemented with 5.6 mM glucose. After incubation, aliquots of cell supernatant were removed for insulin radioimmunoassay [21] . Incubations (n = 8) of BRIN-BD11 cells were also carried out in the presence of 30 mM KCl and 30 mM KCl + 1 µM
[A14K]PGLa-AM1. 
Insulin-release studies using isolated mouse islets
Pancreatic islets were isolated from adult, male National Institutes of Health (NIH) Swiss mice (Harlan Ltd, Bicester, UK) as described [22] . After 48 h of culture under the same conditions as used for clonal cell lines, islets were pre-incubated with 500 µL KRB containing 0.1% bovine serum albumin, and 1.4 mM glucose (pH 7.4) for 1 h at 37 ˚C. Incubations (n = 8)
(positive control) were carried out for 1 h at 37 ˚C using KRB buffer supplemented with 16.7 mM glucose. Aliquots of supernatant were removed for insulin radioimmunoassay and the insulin content of the islets following acid-ethanol extraction was determined as previously described [23] .
Cytotoxicity assay
The effects of peptides upon the integrity of the plasma membrane of BRIN-BD11 cells was determined by measurement of the rate of release of the cytosolic enzyme lactate dehydrogenase (LDH) using a CytoTox 96 non-radioactive cytotoxicity assay kit (Promega, Southampton, UK) according to the manufacturer's instructions as previously described [18, 19] .
Effects of peptides on membrane depolarization and intracellular calcium ([Ca
2+
] i )
The procedure for determining the effects of PGLa-AM1, [A14K]PGLa-AM1, and
[A20K]PGLa-AM1 on membrane depolarization and intracellular Ca 2+ concentrations 8 monolayers of BRIN-BD11 cells has been described previously [18] . The cells were incubated at 37 C for 300 s with 1 µM test peptides, 5.6 mM glucose only, 5.6 mM glucose +30 mM KCl and 5.6 mM glucose +10 mM alanine.
Patch clamp analysis
Full details of the equipment and protocol for patch clamp analysis have been provided previously [23] . K ATP currents were measured during the application of a voltage ramp protocol which initially depolarized the membrane potential to +20 mV and then progressively μM diazoxide. Current amplitudes were sampled at 10 mV intervals, normalized to membrane capacitance (a measure of cell surface area) and statistical analysis completed.
Effects of PGLa-AM1 on cyclic AMP production
The procedure for determining the effects of 1 µM [A14K]PGLa-AM1 and 10 nM GLP-1 (positive control) on the production of cAMP in BRIN-BD11 cells has been described Parameter kit (Abingdon, UK) following the manufacturer's recommended protocol.
Effects of down-regulation of the PKA and PKC pathways on insulin release
It PMA (10nM) and forskolin (25µM) + PMA (10 nM) were also carried out. 
Effects of [A14K]PGLa-AM1on cytokine-induced apoptosis in BRIN-BD11 cells
In vivo insulin release studies
All animal experiments were carried out in accordance with the UK Animals (Scientific National Institutes of Health Swiss mice (Harlan Ltd, Bicester, UK (n =8) has been described previously [26] . Blood samples were collected before and after peptide administration at the different time points shown in Fig. 9 .
In a second series of experiments, mice were maintained for 3 months on a high-fat diet as previously described [19, 27] were collected and analyzed as described for the lean mice.
Statistical Analysis
Data are compared using unpaired Student's t test (non-parametric, with two-tailed P values and 95% confidence interval) and one-way ANOVA with Bonferroni post-hoc test wherever applicable. Area under the curve (AUC) analysis is performed using the trapezoidal rule with baseline correction. Values are presented as mean ± SEM. Results are considered significant if p < 0.05.
Results
Effects of PGLa and analogues on insulin-release from BRIN-BD11 and 1.1B4 cells
The glucose-responsive BRIN-BD111 cell line was generated by electrofusion of rat insulinoma-derived RINm5F cells with New England Deaconess Hospital rat pancreatic islet cells [13] . In the presence of the well-established insulin secretagogue, 10 mM alanine, the rate The 1.1B4 cell line was generated by electrofusion of freshly isolated human pancreatic islet cells with human PANC-1 epithelial cells [14] . It displays good responsiveness to glucose [28] and sensitivity to cytotoxic agents [29, 30] and so represents a useful surrogate for primary 14 human β-cells [31] . As shown in Fig. 2 
Effects of [A14K]PGLa-AM1 and [A20K]PGLa-AM1 on insulin release from isolated mouse islets
In the presence of 16.7 mM glucose, [A14K]PGLa-AM1 and [A20K]PGLa-AM1 produced a concentration-dependent increase in the rate of insulin secretion from dispersed mouse islets (Fig. 3) . A significant stimulatory effects of [A14K]PGLa-AM1 was seen at concentrations ≥ 1nM while [A20K]PGLa-AM1 showed a significant stimulatory effect at 10 nM. These effects were not accompanied by significant release of LDH from isolated islets at any concentration tested. The magnitude of the increase produced by 1 µM concentration of each peptide was not significantly different from that produced by 1 µM GLP-1. Values are mean ± SEM (n = 6). **P < 0.01, ***P < 0.001 compared with 5.6 mM glucose alone.
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The membrane depolarisation produced by the peptides was accompanied by a small but significant (P < 0.05) increase in intracellular calcium concentration ( Figs 5A and B) . The magnitudes of the effects are compared with that produced by 10 mM alanine in Fig. 5C . Patch clamp studies demonstrated that PGLa-AM1 had no significant effect on the K ATP current activated by diazoxide in BRIN-BD11 cells (Fig. 6 ). mean ± SEM (n = 6). *P < 0.05, and **P < 0.01 compared with 5.6 mM glucose alone. 
Effects of [A14K]PGLa-AM1 on apoptosis and cell proliferation in BRIN-BD11 cells
As shown in Fig 
Effects of PGLa analogues on insulin concentrations and glucose tolerance in lean and high-fat fed mice
Administration of the peptides did not produce any apparent adverse effects in the animals. Plasma glucose concentrations in lean mice receiving glucose plus [A14K]PGLa-AM1
(75nmol/kg body weight) (Fig. 9A ) or glucose plus [A20K]PGLa-AM1 (75nmol/kg body weight) (Fig. 9B) were not significantly different at any time point compared with animals receiving glucose only. However, the integrated response of plasma glucose (area under the curve) of the two peptides was significantly (P < 0.05) less after administration of vehicle only (Fig. 9C) . Plasma insulin concentrations were significantly (P < 0.05) higher at 15 min after glucose administration in animals receiving [A14K]PGLa-AM1 (Fig. 9D) or [A20K]PGLa-AM1
( Fig. 9E ) and the integrated response (total amount of insulin released over 60 min) was significantly greater (P < 0.05) for both peptides (Fig. 9F) .
In a second series of experiments using the same protocol, plasma glucose concentrations in high-fat fed mice receiving intraperitoneal A14K]PGLa-AM1) or [A20K]PGLa-AM1 were also not significantly different at any time point compared with injection of glucose alone but the integrated plasma glucose response area under the curve) was significantly (P < 0.05) greater than after administration of both peptides (Supplementary Figure 2) . Similarly, plasma insulin concentrations were significantly (P < 0.05) higher at 15 min after glucose administration in animals receiving [A14K]PGLa-AM1 and the integrated insulin responses were significantly greater for [A14K]PGLa-AM1 (P < 0.01) and for [A20K]PGLa-AM1 (P < 0.05). Values are mean ± SEM (n = 8). *P < 0.05, **P < 0.01 compared to glucose alone.
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Discussion
The global pandemic of T2DM has intensified the search for naturally occurring compounds that may be developed into therapeutic agents that maintain normoglycaemia and prevent or retard the development of the complications associated with the disease. Particular attention has been directed towards compounds that stimulate insulin release (sulphonyureas and incretins) [32] and long acting peptide analogues based upon the structure of the physiologically important incretin GLP-1 have been widely adopted in clinical practice [33] . Norepinephrinestimulated skin secretion of frogs belonging to the family Pipidae, comprising the genera Hymenochirus, Pipa, Pseudhymenochirus and Xenopus [1] , contain a diverse range of peptides whose primary function is probably host-defense (reviewed in [7] ). Several such peptides have been shown to stimulate insulin release from BRIN-BD11 cells at concentrations that are appreciably less than those required to kill microorganisms. These include CPF-6 from Xenopus laevis [34] , CPF-SE1 from Xenopus epitropicalis [34] , hymenochirin-1B from Hymenochirus boettgeri [5] and pseudhymenochirin-1P and -2a from Pseudhymenochirus merlini [20] . ].
As well as lowering blood glucose levels by stimulating insulin secretion, GLP-1 exerts other beneficial effects on glucose homeostasis by suppression of appetite, reduction in plasma glucagon concentrations, and improvement of glucose uptake in peripheral tissues. In addition, GLP-1 [39, 40] and GLP-1 receptor agonists [41, 42] stimulate β-cell proliferation and regeneration, and protect against β-cell damage leading to increased β-cell mass and improved β-cell function. This study has shown that [A14K]PGLa-AM1 shows beta-cell proliferative activity comparable to that of GLP-1 when tested in BRIN-BD11 cells and is equally effective in protecting the cells against cytokine-induced apoptosis (Fig 8) . A role for pro-inflammatory 30 cytokines in promoting β-cell apoptosis is well established [43, 44] . β-cell mass is determined by the relative rates of replenishment and death and T2DM involves a gradual decline in both the function and mass of the β-cells. Consequently, agents such as [A14K]PGLa-AM1, which not only stimulate insulin release but also stimulate β-cell proliferation and reduce β-cell loss, are attractive from a therapeutic prospective.
Finally, the study has shown that [A14K]PGLa-AM1 and [A20K] PGLa-AM1 display anti-hyperglycaemic properties in vivo when administered acutely to lean mice (Fig. 9) . The glucose-lowering and insulin-releasing effects were significant and the magnitude of the changes were comparable those observed following similar administration of equimolar doses of the frog skin peptides phylloseptin-L2 [25] , and brevinin-2GUb [45] . The high-fat fed mouse presents with obesity, hyperglycaemia, and insulin resistance and so is a useful model to study the development of metabolic syndrome and Type 2 diabetes [46, 47] . The present study has demonstrated that [A14K]PGLa-AM1 also lowered blood glucose and enhanced insulin secretion in high-fat fed mice.
In conclusion, PGLa-AM1 and its more cationic 
